Illuminating Myelodysplastic syndromes

By Dr Nicola Davies

Myelodysplastic syndromes (MDS) are a group of disorders that arise from the inadequate functioning of the bone marrow (the spongy material in bones with stem cells), particularly in blood cell production.1 It is considered a form of blood cancer and stems from a lack or abnormal presentation of blood cells. In 2016, worldwide incidence of MDS was between 0.22-13.2 per 100,000 people across all ages, genders and ethnicities.2 Here is a look at MDS, its treatment, and pharma’s role in improving the quality of life of patients with this condition, says Dr Nicola Davies in her exclusive column for The Pharma Letter.

What are Myelodysplastic syndromes?